ReviewCurrent opinion in HIV and AIDS2017
When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.
Review in Current opinion in HIV and AIDS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Roadmap for Achieving Universal Antiretroviral Treatment.Annual review of pharmacology and toxicology · 2023Review
- Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART.BMC medical research methodology · 2021Article
- Article
- The Prevalence and Associated Factors of Hypertension among HIV Patients.International journal of hypertension · 2021Article
- Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis.EClinicalMedicine · 2020Article
- Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naïve patients.Infectious diseases of poverty · 2020Article
- New Insights Into Cryptococcus Spp. Biology and Cryptococcal Meningitis.Current neurology and neuroscience reports · 2019Review
- Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.Journal of acquired immune deficiency syndromes (1999) · 2019Article
- Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.AIDS (London, England) · 2019Article
- Article
- The Use of Efavirenz During Pregnancy is Associated with Suicidal Ideation in Postpartum Women in Rural South Africa.AIDS and behavior · 2019Article
- Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.Journal of the International AIDS Society · 2019Article
- Randomized Controlled Pilot Study of Antiretrovirals and a Behavioral Intervention for Persons With Acute HIV Infection: Opportunity for Interrupting Transmission.Open forum infectious diseases · 2019Article
- Understanding Pathogenesis and Care Challenges of Immune Reconstitution Inflammatory Syndrome in Fungal Infections.Journal of fungi (Basel, Switzerland) · 2018Review
- Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk.Bioanalysis · 2018Article
- Safety Profile of Drug Use During Pregnancy at Peripheral Health Centres in Burkina Faso: A Prospective Observational Cohort Study.Drugs - real world outcomes · 2018Article
- Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.The Lancet. Global health · 2018Observational
- Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review.Journal of virus eradication · 2018Article
- Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?Journal of virus eradication · 2018Article
- Why a universal antiretroviral regimen?Current opinion in HIV and AIDS · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purpose of reviewTo discuss barriers and opportunities for the introduction of new antiretrovirals into national treatment programmes in low-income and middle-income countries to support further treatment scale-up. Invitees to a WHO Think Tank in February 2017 evaluated recently published results. RECENT
findingsThere is not sufficient clinical experience of dolutegravir (DTG), tenofovir alafenamide (TAF) or efavirenz 400 mg (EFV400) to recommend their use in pregnancy. Outcomes from births and assessment of congenital anomalies need to be evaluated from several hundred pregnant women. Clinical experience of these treatments during rifampicin-based treatment for tuberculosis is also required. This could be difficult for TAF, which is currently contraindicated with TAF. Changes in second-line treatment from two nucleoside analogues + protease inhibitor plus ritonavir will require new randomized trials of alternative combinations.
conclusionAdditional safety and efficacy data on DTG, TAF and EFV400 in some subpopulations are needed before a large introduction in national treatment programmes. There is currently limited support for the introduction of TAF as part of first-line antiretroviral treatment in low-income and middle-income settings. There was an overall agreement for 6-monthly reviews of safety and efficacy data, in parallel with a phased introduction of the new antiretrovirals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.